Efficacy assessments
The composite primary efficacy outcome of the PaTHway trial was the proportion of participants at week 26 who achieved albumin‐adjusted serum calcium in the normal range (8.3–10.6 mg/dL [2.07–2.64 mmol/L]), independence from active vitamin D, and independence from therapeutic doses of elemental calcium (>600 mg/d) with no increase in the prescribed study drug over the 4 weeks before week 26. Independence from active vitamin D was defined as a daily standing dose equal to zero on all days and use of any PRN active vitamin D on no more than 7 days during the 4 weeks before the week 26 visit. Independence from therapeutic calcium was defined as an average daily standing dose of ≤600 mg and use of PRN doses on no more than 7 days during the 4 weeks before the week 26 visit. Secondary efficacy outcomes included active vitamin D and elemental calcium doses, daily “pill burden” of active vitamin D and calcium (as oral tablets, powder, liquid solutions, liquid suspensions, or transdermal patches), albumin‐adjusted serum calcium, serum phosphate, and serum calcium × phosphate product.